Akebia Therapeutics (FRA:AX9) Days Payable : 58.35 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Days Payable?

Akebia Therapeutics's average Accounts Payable for the three months ended in Dec. 2023 was €10.9 Mil. Akebia Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was €17.1 Mil. Hence, Akebia Therapeutics's Days Payable for the three months ended in Dec. 2023 was 58.35.

The historical rank and industry rank for Akebia Therapeutics's Days Payable or its related term are showing as below:

FRA:AX9' s Days Payable Range Over the Past 10 Years
Min: 49.57 Med: 96.85 Max: 1169.85
Current: 65.65

During the past 12 years, Akebia Therapeutics's highest Days Payable was 1169.85. The lowest was 49.57. And the median was 96.85.

FRA:AX9's Days Payable is ranked worse than
66.95% of 714 companies
in the Biotechnology industry
Industry Median: 147.95 vs FRA:AX9: 65.65

Akebia Therapeutics's Days Payable increased from Dec. 2022 (0.00) to Dec. 2023 (58.35). It may suggest that Akebia Therapeutics delayed paying its suppliers.

Akebia Therapeutics Days Payable Historical Data

The historical data trend for Akebia Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Days Payable Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

101.73

51.86

87.16

105.59

81.68

Akebia Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															-	72.10	64.68	52.29	58.35

Competitive Comparison of Akebia Therapeutics's Days Payable

For the Biotechnology subindustry, Akebia Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akebia Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Days Payable falls into.

Akebia Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Akebia Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (17.012	+	13.42)	/	2 )	/	67.994	*	365
=	15.216					/	67.994	*	365
=	81.68

Akebia Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (8.469	+	13.42)	/	2 )	/	17.116	*	365 / 4
=	10.9445					/	17.116	*	365 / 4
=	58.35

Akebia Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (FRA:AX9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (FRA:AX9) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

AKBA:USA

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (FRA:AX9) Headlines

No Headlines